The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

@inproceedings{Calvayrac2017TheRG,
  title={The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism},
  author={Olivier Calvayrac and Julien Mazi{\`e}res and Sarah Figarol and Claire Marty-Detraves and Isabelle Raymond-Letron and Emilie Bousquet and Magali Farella and Estelle Clermont-Taranchon and Julie D Milia and Isabelle Rouquette and Nicolas M Guibert and Am{\'e}lie Lusque and Jacques L Cadranel and Nathalie Mathiot and Ariel Savina and Anne Pradines and Gilles Favre},
  booktitle={EMBO molecular medicine},
  year={2017}
}
Although lung cancer patients harboring EGFR mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI), most of them rapidly relapse. RHOB GTPase is a critical player in both lung carcinogenesis and the EGFR signaling pathway; therefore, we hypothesized that it could play a role in the response to EGFR-TKI In a series of samples from… CONTINUE READING